AstraZeneca PLC (AZN)vsKrystal Biotech Inc (KRYS)
AZN
AstraZeneca PLC
$168.10
+0.16%
HEALTHCARE · Cap: $257.57B
KRYS
Krystal Biotech Inc
$350.88
+5.10%
HEALTHCARE · Cap: $9.88B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 13831% more annual revenue ($61.37B vs $440.48M). KRYS leads profitability with a 54.8% profit margin vs 17.0%. AZN trades at a lower P/E of 24.9x. KRYS earns a higher WallStSmart Score of 65/100 (C+).
AZN
Buy60
out of 100
Grade: C+
KRYS
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$168.10
$27.71 discount
Intrinsic value data unavailable for KRYS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Keeps 55 of every $100 in revenue as profit
Strong operational efficiency at 49.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 24.1% year-over-year
Earnings expanding 38.8% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : KRYS
The strongest argument for KRYS centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 54.8% and operating margin at 49.0%. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : KRYS
The primary concerns for KRYS are P/E Ratio. A P/E of 41.9x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while KRYS is a growth play — different risk/reward profiles.
KRYS carries more volatility with a beta of 0.54 — expect wider price swings.
KRYS is growing revenue faster at 24.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
KRYS scores higher overall (65/100 vs 60/100), backed by strong 54.8% margins and 24.1% revenue growth. AZN offers better value entry with a 15.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Krystal Biotech Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?